MCID: TST004
MIFTS: 42

Testicular Lymphoma

Categories: Cancer diseases, Endocrine diseases, Immune diseases, Reproductive diseases

Aliases & Classifications for Testicular Lymphoma

MalaCards integrated aliases for Testicular Lymphoma:

Name: Testicular Lymphoma 39 12 15
Malignant Lymphoma of Testis 12 74
Lymphoma of the Testis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12253
NCIt 51 C6810
UMLS 74 C0349644

Summaries for Testicular Lymphoma

MalaCards based summary : Testicular Lymphoma, also known as malignant lymphoma of testis, is related to follicular lymphoma and plasmablastic lymphoma. An important gene associated with Testicular Lymphoma is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are NF-kappaB Signaling and Dendritic Cells Developmental Lineage Pathway. The drugs rituximab and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include b cells, testis and t cells, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Related Diseases for Testicular Lymphoma

Diseases related to Testicular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 30.0 BCL6 MME
2 plasmablastic lymphoma 29.5 BCL6 PTPRC
3 central nervous system lymphoma 29.5 BCL6 FOXP1 MYD88
4 lymphoma, hodgkin, classic 29.4 BCL6 MME PTPRC
5 b-cell lymphomas 29.4 BCL6 FOXP1 MME
6 mantle cell lymphoma 29.4 BCL6 MME PTPRC
7 peripheral t-cell lymphoma 29.3 BCL6 MME
8 lymphoma, non-hodgkin, familial 29.2 BCL6 MME PTPRC
9 lymphoblastic lymphoma 29.2 BCL6 MME PTPRC
10 diffuse large b-cell lymphoma 29.0 BCL6 FOXP1 MME MYD88
11 lymphoma 10.7
12 primary central nervous system lymphoma 10.2 BCL6 MYD88
13 intravascular large b-cell lymphoma 10.1 BCL6 MME
14 primary mediastinal large b-cell lymphoma 10.1 BCL6 FOXP1
15 t-cell/histiocyte rich large b cell lymphoma 10.1 BCL6 MME
16 plasma protein metabolism disease 10.1 MME MYD88
17 angioimmunoblastic t-cell lymphoma 10.0 BCL6 MME
18 burkitt lymphoma 9.9
19 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.9 BCL6 PTPRC
20 central nervous system hematologic cancer 9.9 BCL6 MME MYD88
21 gamma heavy chain disease 9.9 MYD88 PTPRC
22 colon lymphoma 9.9 BCL6 PTPRC
23 marek disease 9.9
24 epidural neoplasm 9.9 BCL6 PTPRC
25 leukemia, acute lymphoblastic 3 9.8 FOXP1 MME
26 ovarian lymphoma 9.8 MME PTPRC
27 lymphosarcoma 9.8 BCL6 PTPRC
28 lymphoma, mucosa-associated lymphoid type 9.8 BCL6 FOXP1 MME
29 reticulum cell sarcoma 9.8
30 anaplastic large cell lymphoma 9.8
31 sarcoma 9.8
32 reticulosarcoma 9.8 BCL6 PTPRC
33 myasthenia gravis 9.7
34 retinitis pigmentosa and erythrocytic microcytosis 9.7
35 intraocular lymphoma 9.7
36 lymphoproliferative syndrome 9.7
37 patulous eustachian tube 9.7
38 multiple cranial nerve palsy 9.7
39 pancreatitis 9.7
40 acquired immunodeficiency syndrome 9.7
41 hydrocele 9.7
42 myasthenia gravis congenital 9.7
43 heart lymphoma 9.7 BCL6 MME PTPRC
44 hematologic cancer 9.7 BCL6 MME PTPRC
45 lymphatic system cancer 9.7 BCL6 MME PTPRC
46 mature b-cell neoplasm 9.7 BCL6 MME PTPRC
47 leukocyte disease 9.6 BCL6 MME PTPRC
48 marginal zone b-cell lymphoma 9.6 BCL6 FOXP1 MME MYD88

Graphical network of the top 20 diseases related to Testicular Lymphoma:



Diseases related to Testicular Lymphoma

Symptoms & Phenotypes for Testicular Lymphoma

GenomeRNAi Phenotypes related to Testicular Lymphoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.92 BCL6 MYD88 PNLIP PTPRC

MGI Mouse Phenotypes related to Testicular Lymphoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.43 BCL6 MME MYD88 PNLIP POLK PTPRC
2 liver/biliary system MP:0005370 8.92 BCL6 MME PNLIP PTPRC

Drugs & Therapeutics for Testicular Lymphoma

Drugs for Testicular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 1, Phase 2,Phase 2 174722-31-7 10201696
2
leucovorin Approved Phase 2 58-05-9 143 6006
3
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
4
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Vorinostat Approved, Investigational Phase 2,Phase 1 149647-78-9 5311
6
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
7
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
8
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
9
Busulfan Approved, Investigational Phase 2,Early Phase 1,Not Applicable 55-98-1 2478
10
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
11
Iron Approved, Experimental Phase 2 7439-89-6, 15438-31-0 27284 23925
12
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
13
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
14
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
15
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
16
alemtuzumab Approved, Investigational Phase 2 216503-57-0
17
Vidarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 24356-66-9 21704 32326
18
Mycophenolic acid Approved Phase 2,Phase 1,Not Applicable 24280-93-1 446541
19
Carboplatin Approved Phase 2,Not Applicable 41575-94-4 10339178 38904 498142
20
Gemcitabine Approved Phase 2 95058-81-4 60750
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
22
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
23
Etoposide Approved Phase 1, Phase 2,Early Phase 1,Not Applicable 33419-42-0 36462
24
Lenalidomide Approved Phase 1, Phase 2,Phase 2 191732-72-6 216326
25
Thiotepa Approved, Investigational Phase 2,Not Applicable 52-24-4 5453
26
Dasatinib Approved, Investigational Phase 1, Phase 2,Phase 2 302962-49-8 3062316
27
nivolumab Approved Phase 2 946414-94-4
28
Prednisone Approved, Vet_approved Phase 1, Phase 2,Phase 2 53-03-2 5865
29
Vincristine Approved, Investigational Phase 1, Phase 2,Phase 2 2068-78-2, 57-22-7 5978
30
Doxorubicin Approved, Investigational Phase 1, Phase 2,Phase 2 23214-92-8 31703
31
Cytarabine Approved, Experimental, Investigational Phase 2,Not Applicable 147-94-4, 65-46-3 6253
32
Ipilimumab Approved Phase 1, Phase 2,Phase 2 477202-00-9
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
34
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
35
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
36
Oblimersen Experimental, Investigational Phase 2 190977-41-4
37
Doxil Approved June 1999 Phase 1, Phase 2,Phase 2 31703
38 Immunoglobulins Phase 1, Phase 2,Phase 2
39 Antibodies, Monoclonal Phase 1, Phase 2,Phase 2
40 Antineoplastic Agents, Immunological Phase 1, Phase 2,Phase 2
41 Immunoconjugates Phase 1, Phase 2
42 Antibodies Phase 1, Phase 2,Phase 2
43 Immunologic Factors Phase 1, Phase 2,Phase 2,Early Phase 1,Not Applicable
44 Antirheumatic Agents Phase 1, Phase 2,Phase 2,Early Phase 1,Not Applicable
45 Folic Acid Antagonists Phase 2
46 Calcineurin Inhibitors Phase 2,Phase 1,Not Applicable
47 Cyclosporins Phase 2,Phase 1,Not Applicable
48 Antifungal Agents Phase 2,Phase 1,Not Applicable
49 Dermatologic Agents Phase 2,Phase 1,Not Applicable
50 Folate Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
3 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
4 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
5 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
6 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
7 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
8 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
9 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
10 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
11 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
12 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
13 A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) Recruiting NCT02857426 Phase 2 Nivolumab
14 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
15 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
16 Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis Active, not recruiting NCT00945724 Phase 2 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
17 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01839916 Phase 2
18 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
19 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
20 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Active, not recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
21 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Active, not recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
22 Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Terminated NCT01769222 Phase 1, Phase 2
23 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Terminated NCT01419795 Phase 2 lenalidomide
24 MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma Terminated NCT00089076 Phase 1, Phase 2
25 Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma Terminated NCT00088881 Phase 2 prednisone;cyclophosphamide;doxorubicin;vincristine
26 Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL Withdrawn NCT03212807 Phase 2 Durvalumab;Lenalidomide
27 Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Withdrawn NCT02281279 Phase 1, Phase 2 lenalidomide;romidepsin
28 Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
29 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Completed NCT01748721 Phase 1
30 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01658319 Phase 1 fludarabine phosphate;methoxyamine
31 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Completed NCT01567709 Phase 1 Alisertib;Vorinostat
32 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Completed NCT01254578 Phase 1 Lenalidomide
33 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Completed NCT01129193 Phase 1 AR-42
34 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
35 Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Completed NCT00720135 Phase 1
36 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Completed NCT00608361 Phase 1 Dasatinib
37 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma Completed NCT00458731 Phase 1 cediranib maleate
38 Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma Active, not recruiting NCT01815749 Phase 1
39 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Active, not recruiting NCT01678443 Phase 1
40 CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Terminated NCT02168907 Phase 1 6,8-bis(benzylthio)octanoic acid;bendamustine hydrochloride
41 Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Terminated NCT02109224 Phase 1 Ibrutinib
42 Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Terminated NCT01116154 Phase 1 lenalidomide;vorinostat
43 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant Completed NCT01959477 Early Phase 1 busulfan;etoposide;cyclophosphamide
44 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors Completed NCT00536601 Not Applicable etoposide;cyclophosphamide;carmustine;melphalan;busulfan;carboplatin;thiotepa
45 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer Completed NCT00112593 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil
46 Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas Active, not recruiting NCT01793233
47 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma Active, not recruiting NCT00003196 Not Applicable chemotherapy;cyclosporine;mycophenolate mofetil
48 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Active, not recruiting NCT00014235 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil
49 Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma Terminated NCT01408043 Not Applicable plerixafor;etoposide
50 Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma Withdrawn NCT01769911 Not Applicable carmustine;cytarabine;melphalan;etoposide;O6-benzylguanine

Search NIH Clinical Center for Testicular Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Testicular Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Testicular Lymphoma:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Testicular Lymphoma:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Testicular Lymphoma

Anatomical Context for Testicular Lymphoma

MalaCards organs/tissues related to Testicular Lymphoma:

42
B Cells, Testis, T Cells, Bone Marrow, Colon, Brain, Bone

Publications for Testicular Lymphoma

Articles related to Testicular Lymphoma:

(show top 50) (show all 104)
# Title Authors Year
1
Role of 18F-FDG Positron Emission Tomography/Computed Tomography Imaging in Testicular Lymphoma ( 30942064 )
2019
2
Primary testicular lymphoma: A SEER analysis of 1,169 cases. ( 30867741 )
2019
3
T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. ( 30237271 )
2019
4
The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience. ( 30246707 )
2018
5
Posttransplant Lymphoproliferative Disorder Presenting as Testicular Lymphoma in a Kidney Transplant Recipient: A Case Report and Review of the Literature. ( 29666729 )
2018
6
Utility of FDG PET/CT in the Management of Primary Testicular Lymphoma. ( 29889027 )
2018
7
Radiation therapy in primary testicular lymphoma: does practice match the standard of care? ( 29966467 )
2018
8
PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. ( 30026337 )
2018
9
Bilateral hydrocele. Uncommon clinical presentation of primary testicular lymphoma in the elderly. ( 28383626 )
2017
10
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. ( 28356247 )
2017
11
Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution. ( 28612278 )
2017
12
High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with cardiac involvement. ( 28883219 )
2017
13
"The moon on the water": a characteristic ultrasonographic appearance of testicular lymphoma. ( 29135132 )
2017
14
Primary testicular lymphoma. ( 26433344 )
2016
15
Primary testicular lymphoma: Two case reports and review of the literature. ( 26766810 )
2016
16
Straight Vessel Pattern and Rapid Filling Time: Characteristic Findings on Contrast-Enhanced Sonography of Testicular Lymphoma. ( 27335443 )
2016
17
Primary testicular lymphoma. ( 25444963 )
2015
18
Recurrent genomic rearrangements in primary testicular lymphoma. ( 25712539 )
2015
19
Grayscale and color Doppler features of testicular lymphoma. ( 26014335 )
2015
20
Various neurological symptoms by neurolymphomatosis as the initial presentation of primary testicular lymphoma. ( 26034480 )
2015
21
High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses. ( 26388135 )
2015
22
Primary testicular lymphoma: a single centre experience. ( 26422109 )
2015
23
Isolated Central Nervous System Relapse After 10 Years in a Case of Primary Testicular Lymphoma Detected on (18)F-FDG PET/CT. ( 26550055 )
2015
24
Unusual continuous intra-abdominal spread of primary testicular lymphoma along the spermatic cord and gonadal vessels: Report of 2 cases. ( 26649126 )
2015
25
Primary testicular lymphoma with solitary cutaneous nodule as the initial presentation. ( 26664513 )
2015
26
Primary testicular lymphoma with subcutaneous masses as the sole manifestation of the first relapse and central nervous system lymphoma as the second relapse: A case report and literature review. ( 24932252 )
2014
27
Clinical features of testicular lymphoma. ( 24247653 )
2014
28
Primary testicular lymphoma. ( 24282217 )
2014
29
Bilateral primary testicular lymphoma. ( 24692378 )
2014
30
Single-center experience in the treatment of primary testicular lymphoma. ( 24853782 )
2014
31
Scrotal irradiation in primary testicular lymphoma: review of the literature and in silico planning comparative study. ( 22836054 )
2013
32
Three prognostic factors influence clinical outcomes of primary testicular lymphoma. ( 22965883 )
2013
33
Huge testicular lymphoma on 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography-computed tomography. ( 23187303 )
2013
34
Primary testicular lymphoma: experience with 13 cases and literature review. ( 23355262 )
2013
35
Primary testicular lymphoma with rupture: An unusual presentation. ( 23633871 )
2013
36
Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma. ( 23680437 )
2013
37
Intraocular (vitreoretinal) lymphoma following primary testicular lymphoma. ( 23931497 )
2013
38
Testicular lymphoma. ( 23945480 )
2013
39
F18 FDG positron emission tomography revelation of primary testicular lymphoma with concurrent multiple extra nodal involvement. ( 24019676 )
2013
40
Primary diffuse large B-cell testicular lymphoma: magnetic resonance imaging findings. ( 21988565 )
2012
41
FDG PET/CT of bilateral testicular lymphoma. ( 22157041 )
2012
42
Primary testicular lymphoma. ( 22424983 )
2012
43
Primary testicular lymphoma with cardiac involvement in an immunocompetent patient: case report and a concise review of literature. ( 23087799 )
2012
44
Clinics in diagnostic imaging (134). Testicular lymphoma. ( 21451930 )
2011
45
Relapsed testicular lymphoma presenting with cranial nerve neurolymphomatosis. ( 21502608 )
2011
46
Primary testicular lymphoma and AIDS. ( 20124334 )
2010
47
Primary testicular lymphoma: a strictly homogeneous hematological disease? ( 20372839 )
2010
48
Primary testicular lymphoma: the site matters. ( 20497004 )
2010
49
Testicular lymphoma, intraocular (vitreoretinal) lymphoma, and brain lymphoma: involvement of three immunoprivileged sites in one patient. ( 20658596 )
2010
50
Primary testicular lymphoma. ( 20872294 )
2010

Variations for Testicular Lymphoma

Expression for Testicular Lymphoma

Search GEO for disease gene expression data for Testicular Lymphoma.

Pathways for Testicular Lymphoma

Pathways related to Testicular Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 BCL6 MYD88 PTPRC
2 11.13 MME PTPRC
3 10.52 BCL6 MME PTPRC
4 10.46 MME PTPRC

GO Terms for Testicular Lymphoma

Cellular components related to Testicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule membrane GO:0030667 8.62 MME PTPRC

Biological processes related to Testicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 B cell differentiation GO:0030183 9.4 BCL6 PTPRC
2 positive regulation of smooth muscle cell proliferation GO:0048661 9.37 FOXP1 MYD88
3 positive regulation of tumor necrosis factor production GO:0032760 9.32 MYD88 PTPRC
4 positive regulation of B cell proliferation GO:0030890 9.26 BCL6 PTPRC
5 negative regulation of B cell apoptotic process GO:0002903 9.16 BCL6 FOXP1
6 regulation of tumor necrosis factor production GO:0032680 8.96 FOXP1 MYD88
7 regulation of inflammatory response GO:0050727 8.8 BCL6 FOXP1 MYD88

Molecular functions related to Testicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein self-association GO:0043621 8.62 FOXP1 MYD88

Sources for Testicular Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....